Theraclion has reported the activity under its liquidity contract with Crédit Industriel et Commercial for the first half of 2026. As of June 30, 2026, the liquidity account held 26,499 shares and €3,355.99. This contract is managed to ensure liquidity for the company's shares listed on Euronext Growth Paris.

Trading Activity for H1 2026

During the first half of 2026, the liquidity provider executed a total of 1,985 transactions. The trading activity involved both purchases and sales of Theraclion shares on the market.

The following table details the buy and sell transactions executed by the liquidity provider during the period:

Liquidity Account Status

The resources held in the liquidity account at the end of the period represented a change from the initial holdings at the time the contract was signed. At the signing of the contract, the account held 31,850 shares and €27,935.01.

Theraclion is a French MedTech company developing non-invasive alternatives to surgery using focused ultrasound. The company is listed on Euronext Growth Paris and is eligible for the PEA-PME scheme.

Theraclion has appointed Vincent Gardès as Chairman of its Board of Directors, effective immediately, to strengthen its governance during a period of commercial expansion and regulatory progress. The appointment follows the company's recent achievements, including MDR certification, the first clinical implementation in China, and the submission of its Sonovein® file to the FDA. Gardès succeeds Claude Lenoir, who served as Interim Chairman since June 18, 2026, and remains a Director of the company.

The Board of Directors met on July 8, 2026, to finalize the appointment. Gardès has been a Director since the General Meeting of June 18, 2026, after serving as an observer in recent months. His appointment comes as Theraclion gains commercial momentum in Europe and secures a Category III CPT code in the United States. The company also recently completed a successful capital increase.

Strategic Milestones

Theraclion has reached several key milestones that position it for growth:

• MDR Certification: Achieved under EU 2017/745 for Sonovein®.
• FDA Submission: The Sonovein® file has been submitted for review.
• US Market Access: Granted a Category III CPT code.
• Global Expansion: First clinical implementation in China and growing adoption in Europe.

Vincent Gardès is a recognized MedTech executive with 30 years of experience in value creation for innovative medical devices. He previously served as CEO of Vexim, leading the company through its acquisition by Stryker. He also led Germitec's commercial development in Europe and entry into the US market, and currently leads Amber Implants through its commercialization phase.

Leadership Commentary

Vincent Gardès expressed his commitment to accelerating Theraclion's commercial strategy. "I am honoured by the trust placed in me by the Directors of Theraclion. The company has a unique technology, solid clinical results and remarkable momentum across all of its markets: in Europe, where Sonovein® is already adopted in clinical practice, and in the United States, where the fundamentals of market access are falling into place," he stated.

Martin Deterre, Chief Executive Officer of Theraclion, highlighted the strategic value of the appointment. "The appointment of Vincent Gardès is excellent news for Theraclion. His track record in the international development of innovative MedTech companies is exactly what Theraclion needs today. We have been working together for several months; this collaboration is already remarkably smooth and we fully share the same strategic vision," Deterre said.

About Theraclion

Theraclion is a French MedTech company developing Sonovein®, a robotic platform using High-Intensity Focused Ultrasound (HIFU) for non-invasive varicose vein therapy. The technology requires no incisions or operating room, leaves no scars, and allows patients to resume daily activities immediately. Sonovein® has been adopted by more than a dozen centres worldwide and used in over 4,000 procedures. The company is based in Malakoff, Paris, and employs approximately 40 people.